focus -WSS

focus

author：leisure time 2025-09-05 09:20:25 - browse：2352

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： PBM executives asked to testify by House panel

WSS

BIO to announce reorganization, senior leaders expected to depart

Black vets could get higher VA benefits if race not used in lung test

Most antidepressants don't work on kids, teens, study finds

Novel spinal cord stimulator treats paralysis without surgery

Chemotherapy before breast cancer surgery might fuel metastasis

Crowdfunding for medical bills sidesteps core problem, author says

hotspot

focus

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

Deliver public health messages at the right time

Bright Health sells Medicare Advantage business to Molina

Class action alleges UnitedHealth concealed DOJ probe

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Class action alleges UnitedHealth concealed DOJ probe

State Dept. review finds Biden bears some blame for Afghanistan failures

Chemotherapy before breast cancer surgery might fuel metastasis

Jerome Adams on the need for new antivirals for Covid

The creative science of coining drug names

hotspot

AltruBio raises $225 million to develop ulcerative colitis drug

Empower primary care with adequate payments and technology

HHS's proposed rule does nothing to address the climate crisis

Is it ever OK for doctors to lie to their patients?

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Can gargling with Listerine treat gonorrhea of the mouth?

knowledge

entertainment

Wikipedia

hotspot